Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report iShares S&P Mid-Cap 400 Growth ETF (IJK): ETF Research Reports Roku, Inc. (ROKU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Earnings estimates for ARWR from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Get free trial access to our live API and historical testing files now! with fundamental company data provided by Morningstar and Zacks Investment Research. Three Pivotal Studies, Value-Inflection Opportunities In View. September 27, 2019 12:15 pm Zacks Small Cap Research 0. By Brian Marckx, CFA. NASDAQ:ARWR. READ THE FULL ARWR RESEARCH REPORT. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the Cantor Fitzgerald upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a neutral rating to an overweight rating in a research report sent to investors on Wednesday, 24/7 WallStreet reports. Cantor Fitzgerald currently has $60.00 price target on the biotechnology company's stock, up from their prior price target of $55.00. A number of other research analysts have […] Brokerages expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to post $0.34 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Arrowhead Pharmaceuticals' earnings, with the lowest EPS estimate coming in at $0.10 and the highest estimate coming in at $0.76.
Get the latest Arrowhead Pharmaceuticals Inc ARWR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Arrowhead Pharmaceuticals, Inc. - ARWR - Stock Price Today - Zacks ARWR
About Investor's Business Daily - Investor's Business Daily provides exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 34 cents per share. The drug developer posted revenue of $42.7 million in the period, which also did not meet Street forecasts. Four analysts surveyed by Zacks expected $59.1 million. SOXX | A complete iShares PHLX Semiconductor ETF exchange traded fund overview by MarketWatch. View the latest ETF prices and news for better ETF investing. Arrowhead Pharmaceuticals, Inc. ARWR is scheduled to release first-quarter fiscal 2020 results on Feb 5, after market close. The company missed earnings estimates in three of the trailing four quarters by 33.37%, on average. In the last reported quarter, Arrowhead came up with a negative earnings surprise of 21.43%.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, Quote ...
Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. The ABR is the calculated average of the actual recommendations
ARWR: Arrowhead Pharmaceuticals Inc broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.
First Trust Mid Cap Growth AlphaDEX Fund holds a Zacks ETF Rank of 1 (Strong Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Historical daily share price chart and data for Arrowhead Pharmaceuticals since 1997 adjusted for splits. The latest closing stock price for Arrowhead Pharmaceuticals as of June 05, 2020 is 34.07.. The all-time high Arrowhead Pharmaceuticals stock closing price was 162.34 on March 16, 2000.; The Arrowhead Pharmaceuticals 52-week high stock price is 73.72, which is 116.4% above the current ARWR Stock Message Board for Investors. Arrowhead Pharmaceuticals Inc. Stock Price, News and Company Updates. Message Board Total Posts: 64 Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $35.03 to a high of $37.26. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high The Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are Delighted Simply Wall St. Oct-23-19 01:25PM : Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey: Oct-18-19 04:38PM : Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout Investor's Business Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) changed hands in heavy trading on Wednesday after the company announced an equity offering before the market opened. Having reported earnings last week that smashed estimates and sent the stock to all-time highs, this was a nasty surprise to investors and a timely reminder of the risks inherent to biotech stocks.
The Dividend History page provides a single page to review all of the aggregated Dividend payment information. Visit our Dividend Calendar: Our partner, Zacks Investment Research, provides the upcoming ex-dividend dates for the next month.
PASADENA, Calif. (AP) _ Arrowhead Research Corp. (ARWR) on Thursday reported a fiscal second-quarter loss of $19.8 million, after reporting a profit in the same period a year earlier. On a per ARWR earnings call for the Arrowhead received $75 million in the form of an equity investment by Johnson & Johnson Innovation-JJDC, Inc., at a price of $23 per share of Arrowhead common stock View target prices and earnings history for Arrowhead Pharmaceuticals Inc. [ARWR:US] with TMXmoney. Top. Home Market Activity Get Quotes Research Zacks Investment Research. analyst ratings/earnings by Zacks. Avrobio (NASDAQ:AVRO) Stock Rating Upgraded by Zacks Investment Research Arrowhead Pharmaceuticals (NASDAQ:ARWR) Cut to "Hold" at ValuEngine Needham & Company LLC Cuts SS&C Technologies Passage Bio (NYSE:GFL) Stock Rating Lowered by Zacks Investment Research Q3 2020 EPS Estimates for Arrowhead Pharmaceuticals Inc Cut by B. Riley (NASDAQ:ARWR) Lear Co. (NYSE:LEA) Short Interest Up